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The advent of new medications and new treatment
strategies for rheumatoid arthritis has made it possible
to achieve remission in more patients than before.
Furthermore, recent clinical trials and register studies
suggest that some patients who initially required
aggressive therapy may achieve biologic-free remission
or even the ultimate goal of therapy, drug-free remission,
resembling recovery. Here, we present a discursive
review of the most important studies addressing
these issues. Based on the overall results, it remains
unclear if achieving biologic-free and drug-free
remissions are primarily due to the natural course of
the disease or to the early therapeutic intervention
according to the ‘window of opportunity’ hypothesis.
Although medication-free remission is only achievable
in a small subset of patients, characterizing this patient
cohort may provide important information about
beneficial prognostic factors and the underlying
mechanisms. In summary, in a subset of patients
biologic-free and even drug-free remission can be
achieved; pursuing these possibilities in practice may
decrease the risk for long-term side effects and attenuate
the economic burden of the disease.and HLA-DRB1, environmental factors also have a centralBackground
Early control of inflammation in rheumatoid arthritis (RA)
generally results in better outcomes; thus, the current treat-
ment strategy is to initiate aggressive therapy as soon as
possible after diagnosis has been established, and to extend
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unless otherwise stated.clinical remission [1] (Fig. 1). Currently we have many syn-
thetic and biological disease modifying antirheumatic drugs
(sDMARD and bDMARD, respectively) to achieve this aim.
With appropriate use of biologicals and tight control strat-
egies, remarkable improvement is achievable in clinical out-
comes, and remission is possible in an increasing numbers
of patients. Lifelong treatment with bDMARDs is very
expensive and entails potential long-term side effects.
According to the EULAR recommendations [2], if a patient
is in remission, bDMARD and in the case of sustained re-
mission even sDMARD therapy might be tapered. Here we
summarize the current understanding of biologic-free and
drug-free remission in RA.
Paradoxically, we know much more about optimal initi-
ation than about optimal termination of pharmacotherapy
in RA [3]. Sustained clinical remission is achieved in 20 to
40 % of patients, and generally requires ongoing therapy,
but bDMARDs and/or sDMARDs may be able to be ta-
pered for some of this patient group. A small but not
inconsiderable proportion of patients with RA may have a
chance for drug-free remission, which might be due to the
natural course of the disease and/or to the therapies used;
the key question is whether currently available medications
may alter this chance [4].
In addition to genetic risk factors, such as PTPN22
role in the pathogenesis of RA [5]. Cigarette smoking is
the best established environmental risk [6], while moder-
ate alcohol consumption seems to be protective. The pro-
duction of anti-citrullinated protein antibodies (ACPAs)
and rheumatoid factor (RF) before the onset of the disease
has been shown and these are associated with initiation of
autoimmunity and loss of tolerance towards self structures
[7]. Genetic and environmental factors together with un-
known triggers (infections and so on) may directly lead to
initiation of RA. Regulatory T helper cells appear to have
a role in peripheral tolerance, and impaired function of
these cells may contribute to a loss of immune toleranceOpen Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Fig. 1 Phases of rheumatoid arthritis - a hypothetical model. Question marks indicate hypothetical statements. CCP, cyclic citrullinated peptide; RA,
rheumatoid arthritis; RF, rheumatoid factor; SE, shared epitope
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immune systems is characteristic; due to accelerated
osteoclast differentiation and activation, bone erosions
develop in the first months after the onset of the disease
and are generally associated with sustained inflammation.
RA is characterized by an increased risk of cardiovascular
disease, such as cerebrovascular events, heart failure, myo-
cardial infarction, and shorter life expectancy than the
general population [9].
It is widely accepted that cytokine production by many
cell populations of the inflamed synovium has a central
role in the pathogenesis of RA. Furthermore, several lines
of evidence support that a complex network of proinflam-
matory cytokines and numerous positive feedback loops
perpetuate the chronic inflammation. Biologicals may
substantially remodel the network of cytokines, leading
to significant clinical improvement [10]. Interleukin (IL)-1,
IL-6, IL-17, IL-18, and IL-33 and tumor necrosis factor
(TNF) are overexpressed in RA. While TNF and IL-6
blockade are effective treatment options, the effectiveness
of IL-1 inhibition is rather modest. According to theavailable data, the effect of the IL-17 blocker secukinumab
appears to be also moderate [11, 12]. The possible rea-
son for the variation in the clinical benefit of cytokine
blocking-based therapeutic approaches is that cytokine-
driven inflammation [13] might be distinct between in-
dividual RA patients.
Remission induction and tapering biologicals
According to the concept of the ‘window of opportunity’
[14–16], aggressive treatment in the early phase of the
disease may lead to excellent improvement and sustained
benefit (Fig. 1). It is hoped that remission induction in the
window of opportunity allows medications to be tapered
in the medium term to maintenance therapy. This concept
is supported by the observation that therapeutic response
in the first 3 months of therapy predicts the potential
of reaching remission later [17]. A potential explanation
for the effectiveness of early intervention is that auto-
immunity might not be fully established during this phase.
Several studies have investigated tapering biologicals.
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responses after the termination of a biological therapy.
Patients with early RA (<12 months of symptoms, 65 %
RF-positive) were treated with methotrexate (MTX), and
were randomized to be treated with infliximab or placebo
for 12 months. Patients were followed for an additional
12 months. The primary endpoint of this double blind
study was synovitis, measured by magnetic resonance
imaging (MRI). At 12 months the American College of
Rheumatology (ACR)50 and ACR70 responses were better
in the MTX plus infliximab group (P < 0.05 and P < 0.05,
respectively), no new erosions were found, and the MRI
scores were significantly better than in the MTX plus pla-
cebo group. More remarkably, 1 year after the discontinu-
ation of infliximab, 70 % of patients still had sustained
excellent clinical response, and the quality of life and func-
tional advantages were still manifest, thereby supporting
the window of opportunity hypothesis.
The Behandel-Strategieën (BeSt) study clearly showed
that a treat-to-target approach provides sustained clinical
and radiological benefit in RA [19, 20]. In this study
patients were randomized to four remission induction
treatment groups: group 1, sequential monotherapy (n =
126); group 2, step up combination therapy (n = 121);
group 3, initial combination with prednisone (n = 133);
group 4, initial combination with MTX and infliximab
(n = 128). The maximum disease duration was 2 years.
Disease Activity Score (DAS) was measured every
3 months, and medications were adjusted according to
the actual disease activity. The goal in all treatment
arms was to reduce disease activity as soon and as ef-
fectively as possible. DAS44 ≤ 2.4 was defined as good
clinical response, and if DAS44 was >2.4, the next
treatment step was applied. The medication was tapered
to monotherapy if DAS44 was ≤2.4 for at least half a year.
In group 1 treatment was started with MTX 15 mg/week
and in the case of insufficient response the dose of MTX
was raised to 25 mg/week, then changed to the next
medications: sulphasalazine (SSA); leflunomide; MTX plus
infliximab with stepwise increases in infliximab dose from
3 mg/kg to 10 mg/kg; gold; MTX plus ciclosporin (CSA)
plus prednisone; azathioprine (AZA) plus prednisone. In
group 2, patients with inadequate response to MTX re-
ceived the following treatments: MTX plus SSA; MTX
plus SSA plus hydroxychloroquine (HCQ); MTX plus
SSA plus HCQ plus prednisone; MTX plus infliximab
with increasing infliximab doses as in group 1; MTX
plus CSA plus prednisone; gold; AZA plus prednisone.
In group 3 the order of treatments was: MTX plus SSA
plus prednisone; MTX plus CSA plus prednisone; MTX
plus infliximab with increasing infliximab doses as in
group 1; leflunomide; gold; AZA plus prednisone. The
order of treatments in group 4 was: MTX plus infliximab
with increasing MTX doses from 15 to 25 mg/week,then with increasing infliximab doses as in group 1; SSA;
leflunomide; MTX plus CSA plus prednisone; gold; AZA
plus prednisone.
In group 4 43 % of patients were in remission (DAS44 <
1.6) and 56 % completed infliximab treatment during the
first 2 years of the study [19]. In a post hoc analysis of all
four groups, 45 % of patients could discontinue the bio-
logical therapy and 52 % of these patients did not restart
during the 7.2 year median follow-up time [20]. Shared
epitope (SE) positivity, smoking and prolonged infliximab
treatment were associated with restarting infliximab; that
is, with the inability to maintain remission without the
anti-TNF agent. Conversely, SE negativity, non-smoking
and shorter anti-TNF treatment were predictors for sus-
tained biologic-free remission.
In the Infliximab as Induction therapy in Early
Rheumatoid Arthritis (IDEA) study (a 78 week, double-
blind, randomized, controlled study) remission induction
with MTX plus infliximab and MTX plus high-dose intra-
venous steroid were compared in a treat-to-target approach
[21]. This study included 112 DMARD-naïve patients with
early RA (3 to 12 months symptom duration). All patients
received at least 10 mg/week MTX, increased to 20 mg/
week or to maximum tolerated dose. Patients were random-
ized to receive either 3 mg/kg infliximab according to the
standard protocol, or 250 mg intravenous methylprednisone
at week 0 and placebo infusions at weeks 2, 6, 14 and 22.
From week 26, in the unblinded, open label phase of the
study patients with an inadequate response (DAS44 > 2.4) in
the infliximab group were treated with increased infliximab
doses (up to 10 mg/kg), or biological therapy was stopped
and MTX was changed to other sDMARDs. In the high
dose steroid group, if DAS44 was >2.4, the following treat-
ments were applied: MTX plus SSA plus HCQ; then MTX
plus leflunomide; oral MTX was changed to subcutaneous
MTX; CSA plus subcutaneous MTX; CSA plus subcutane-
ous MTX plus oral prednisone. Infliximab was stopped if
DAS44 was <1.6 for 6 months. Overall there was no signifi-
cant difference in the efficiency of the two therapeutic strat-
egies; 24.5 % (14/55) of the patients discontinued infliximab
therapy due to sustained remission, and 76 % (11/14) of
those were still in remission at the end of the study.
The Japanese Remission Induction by Remicade in RA
(RRR) study [22] was designed to investigate if infliximab
(3 mg/kg) with concomitant MTX might be stopped in
patients with persistent low disease activity (DAS28 < 3.2
for >24 weeks). The mean disease duration was 5.9 years
and the mean DAS28 score was 5.5 at baseline. The pri-
mary endpoints were: 1, low disease activity after dis-
continuing infliximab at 1 year; 2, modified total Sharp
score (mTSS) progression <0.5 at 1 year. Of the 102 pa-
tients rated at year 1, 55 % (56) were able to discontinue
infliximab (RRR-achieved) and 44 (43 %) reached remission
(DAS28 < 2.6). Within 1 year after stopping infliximab 29
Nagy and van Vollenhoven Arthritis Research & Therapy  (2015) 17:181 Page 4 of 7patients had flared. The mTSS was comparable in the
RRR-achieved and RRR-failed patient groups. Patients who
were able to discontinue infliximab were younger, had
lower mTSS and had shorter disease duration, further
supporting the window of opportunity hypothesis.
In the recently published 78 week randomized, double
blind Optimal Protocol for Methotrexate and Adalimumab
Combination Therapy in early Rheumatoid Arthritis
(OPTIMA) trial, MTX naïve patients with early RA
(disease duration <1 year) were randomized to receive
either adalimumab (40 mg biweekly) plus MTX or placebo
plus MTX therapy for 26 weeks (period 1) [23]. After
26 weeks, patients who reached stable low disease activity
(DAS28 < 3.2) were randomized either to continue or to
stop adalimumab, and were followed for an additional
52 weeks (period 2). Forty-four percent of patients who
were treated with adalimumab and MTX (as induction
therapy) reached low disease activity. Importantly, the
benefit was often maintained after cessation of adalimumab
therapy: 82 of 101 patients had DAS28 < 3.2 at week 78,
suggesting that MTX maintenance is effective in most
patients following successful induction therapy.
The High Induction Therapy with Anti-Rheumatic Drugs
(HIT HARD) study investigated the effect of induction
therapy with MTX plus adalimumab [24]. Patients with
early RA (average disease duration <1 year) were random-
ized 1:1 into MTX plus placebo and MTX plus adalimumab
in this 48-week trial. After week 24 all patients continued
MTX monotherapy. The primary outcome was DAS28 at
week 48. At week 24 the remission rates were significantly
higher in the adalimumab plus MTX group (P= 0.009). In
the MTX plus adalimumab arm 45 % of patients were in
remission (DAS28 < 2.6) at week 24, and about 90 % of
those were still in remission at week 48, further supporting
that MTX maintenance therapy is effective in a significant
proportion of patients for sustaining remission after the ces-
sation of biological therapy. However, there was no statisti-
cally significant difference between the two arms in clinical
efficacy at week 48.
Initial MTX monotherapy (group 1) and the combin-
ation of MTX with adalimumab (group 2) in early RA
(maximum disease duration 6 months) were compared in
the prospective, unblinded, randomized, 1 year GUEPARD
trial [25]. In case of insufficient response at week 12 in
group 1, patients were treated with MTX plus adalimu-
mab, MTX plus etanercept, or MTX plus leflunomide. In
group 2, if the DAS28 was <3.2, adalimumab was stopped;
39 % of patients in group 2 had low disease activity from
week 12 until the end of the study while receiving MTX
monotherapy. There was no significant difference in clin-
ical or radiological outcomes between the two groups. It is
important to point out that both the HIT HARD and the
GUEPARD trials may have been underpowered to detect
the true long-term effects of early anti-TNF therapy.Drug-free remission
In addition to decreasing the signs and symptoms of
RA, early and aggressive therapy may also improve the
underlying immune disturbance, leading to drug-free re-
mission in a small subset of patients. Drug-free remission
has been described in several patient groups.
In the BeSt study, after the second year, if the DAS44
was <1.6 for at least half a year, the DMARD was tapered
and discontinued. Thirteen percent of the patients were in
medication-free remission after 4 years [26]. Male gender,
lack of ACPA and short symptom duration were asso-
ciated with drug-free remission. Furthermore, 48 % of
patients were in remission and 14 % in drug-free remis-
sion after 5 years; 14 %, 16 %, 10 %, and 19 % of patients
reached medication-free remission in groups 1 to 4 after
5 years [27]. It is uncertain if the treat-to-target strategy or
the natural course of the disease (irrespective of the drugs
used) had more influence on the successful tapering of
the medications. Although the initial combination ther-
apy with MTX and infliximab led numerically to the most
favorable result in terms of achieving drug-free remission
(19 %), further studies are needed to clarify if there is signifi-
cant difference between the strategies in reaching this aim.
The prevalence of and predictive factors for medication-
free remission were studied in the British Early Rheuma-
toid Arthritis Study (ERAS) cohort and in the Leiden
Early Arthritis Clinic (EAC) cohort (prospective inception
cohorts) [28]. All patients were treated with sDMARDs.
Sustained medication-free remission (defined as no syno-
vitis after terminating the DMARD therapy) was observed
in 15 % of the patients in the EAC and 9.4 % in the
ERAS cohort. Short symptom duration, SE-negativity,
RF-negativity, acute onset, not smoking and minimal
radiographic damage were associated with drug-free re-
mission in both patient cohorts.
The chance for sustained drug-free remission was com-
pared retrospectively in the case of DAS-driven and non-
DAS-driven therapy [29]. Patients included in the BeSt
study (a randomized treatment cohort) received DAS-driven
therapy, while patients in the EAC cohort were treated in a
non-DAS-driven way. The prevalence of medication-free re-
mission was comparable in the DAS-driven (9.8 %) and non
DAS-driven (10.6 %) cohorts. Although ACPA-positivity is
associated with worse prognosis, ACPA-positive patients
had a better chance for drug-free remission if they were
treated in a DAS-driven way. The absence of RF and ACPA,
SE-negativity, male gender, lower health assessment ques-
tionnaire (HAQ) score and DAS at baseline were associated
with sustained drug-free remission in the DAS-guided co-
hort [29]. In both cohorts short symptom duration and lack
of ACPA were independent prognostic factors for drug-free
remission.
The Etanercept and Methotrexate in Patients to Induce
Remission in early Arthritis (EMPIRE) trial compared the
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for remission induction [30]. DMARD-naïve patients with
early inflammatory arthritis (less than 3 months disease
duration) and either RF-, ACPA- or SE-positivity were in-
cluded in this 78-week randomized superiority trial. The
primary endpoint was no tender or swollen joint at week
52. Patients received placebo or etanercept injections until
they had no tender and swollen joint for 26 weeks, and at
week 52 all patients stopped receiving injections. After the
cessation of etanercept or placebo, if patients were in re-
mission for at least 12 weeks, MTX was discontinued.
There was no difference between the patient groups in
achieving the primary endpoint. In both groups 3.6 % of
patients reached sustained drug-free remission at week 78,
suggesting that early treatment with etanercept does not
increase the chance for drug-free remission.
In the PRIZE study, patients with early RA who reached
remission (DAS28 < 2.6) following treatment with 50 mg
etanercept plus MTX for 52 weeks were randomized to
25 mg etanercept plus MTX, MTX monotherapy, or pla-
cebo arms for 39 weeks [31], then all medications were
stopped and the patients were monitored for an additional
26 weeks. At week 117, after treatment withdrawal, 42 %,
30 % and 22 % in the etanercept plus MTX, MTX mono-
therapy, and placebo arms, respectively, were still in re-
mission. This means that 22 % of patients who were in
remission with 50 mg etanercept and MTX were still in
remission more than 1 year after the cessation of both
drugs.
In the Assessing Very Early Rheumatoid arthritis Treat-
ment (AVERT) trial the efficacy and safety of abatacept
were studied in ACPA-positive patients with early (active
synovitis for ≥8 weeks) RA [32]. Patients were randomized
to 12 months abatacept plus MTX treatment, or to abata-
cept monotherapy or MTX monotherapy arms. Patients
with DAS28 < 3.2 at month 12 entered another 12-month
period with no treatment: 14.8 %, 12.4 % and 7.8 % of pa-
tients in the abatacept plus MTX, abatacept monotherapy
and MTX monotherapy arms, respectively, were in remis-
sion (DAS28 < 2.6) at both 12 and 18 months. A signifi-
cantly higher percentage of patients in the abatacept plus
MTX arm were in remission at both 12 and 18 months
compared with the MTX arm (P = 0.01 and P = 0.045,
respectively), but there was no meaningful difference
between the abatacept monotherapy and MTX arms at
either time point. Drug-free remission was associated with
lower baseline symptom duration, lower initial DAS28
and lower HAQ score.
The 3-year double-blind ACT-RAY study was designed
to investigate the efficacy of tocilizumab plus MTX in
RA using a treat-to-target strategy [33]. Patients who were
in sustained remission discontinued tocilizumab, and if re-
mission was maintained, sDMARDs were stopped as well:
50.4 % of patients stopped tocilizumab and eventually5.9 % achieved drug-free remission. Although the majority
of patients who quit the bDMARD flared, reintroducing
tocilizumab led to clinical improvement in most cases.
The prevalence of drug-free remission among patients
treated with tocilizumab monotherapy (DREAM study)
was also investigated recently [34]. Ten percent of patients
were able to discontinue tocilizumab therapy. Low matrix
metalloproteinase 3 and low serum IL-6 levels were pre-
dictors of low disease activity.
Some limitations of the studies discussed here should
be acknowledged. Complete molecular remission may
not happen in all patients who are in clinical remission,
and therefore some radiographic progression may occur
even during clinical remission. It is possible that some of
the patients who could completely stop all medications
and had sustained remission did not have RA. Although
the 1987 classification criteria [35] were used in the ma-
jority of these studies (except the EMPIRE and the AVERT
trials; all patients in EMPIRE had early inflammatory arth-
ritis and not all fulfilled the 1987 classification criteria
[30]; in the AVERT trial, patients were described as early
RA [32]), some misclassification may have occurred.
However, the similar rates of medication-free remission
in the different patient populations (different cohorts,
different serological features), chronic polyarthritis and
the structural joint damage described for most patients
argue against misclassification in these studies.
Translating pathogenesis into clinical phases, a
hypothetical model
Our hypothesis is that, in accordance with the window
of opportunity theory, the potential reversibility of auto-
immunity decreases over time in RA and this alters the
potential efficacy of therapies. Based on our hypothesis
and the features of the different phases of RA, pre-disease
phase individuals with ACPA-, RF- and SE-positivity have
a significant risk for RA, especially if they have arthralgia
(Fig. 1) and the risk is further increased in smokers.
This phase, when autoimmunity is already present, can
be transformed into definitive RA, the window of oppor-
tunity phase, which is associated with the acceleration of
autoimmunity, further loss of tolerance in molecular level
and unequivocal clinical symptoms. This phase is char-
acterized by increased production of proinflammatory
cytokines and consequential synovitis, osteoclast activa-
tion and development of erosions. In the early phase of
the disease aggressive therapy leads to disproportionate
benefits and patients have a good chance for remission,
and even drug-free remission might be feasible. Import-
antly, autoimmunity appears to be reversible in this phase
in some patients. Since autoimmunity is characterized
by the loss of tolerance toward self-structures [7], drug-
free remission at the molecular level probably means
not only complete suppression of disease activity, but also
Nagy and van Vollenhoven Arthritis Research & Therapy  (2015) 17:181 Page 6 of 7the re-establishment of tolerance. Improved function of
regulatory T helper cells is likely necessary for the re-
covery of normal immunological tolerance. Later, in the
progressive phase of the disease, autoimmunity is no lon-
ger reversible, and chronic synovitis and lasting cytokine
imbalance lead to further structural damage. In this late
phase adequate therapy leads to moderate benefit, patients
have a low chance of remission and there is no chance for
drug-free remission.
In all probability, different treatment strategies with
distinct effects on the cytokine cascades specify the chance
of medication-free remission. This model suggests that,
among other known and unknown factors, disease dur-
ation is a crucial risk factor for progressive disease, which
is generally characterized by irreversible autoimmunity.
Conclusions
Available clinical trials have demonstrated that appropri-
ate therapy, initiated during the window of opportunity,
may lead to rapid and sustained improvement in RA,
frequently enabling the cessation of biologicals and in
some cases all medications might be tapered. Although
only a few trials aimed to study drug-free remission, there
is some evidence that biologicals increase its likelihood;
there might be differences between medications in this
respect. As it seems the prevalence of medication-free re-
mission is now around 3.6 to 22 %, further studies are
needed to select the most favorable treatment strategies.
The possible roles of disease duration, environmental and
genetic factors should be investigated as well. It is crucial
to identify those patients who have a realistic chance to
taper medications; reliable biomarkers are needed to reach
this aim. It is especially important to understand the condi-
tions that lead to the re-establishment of tolerance during
remission. Understanding the mechanism of drug-free
remission at the molecular level might provide invaluable
information to develop curative therapeutics in RA.
Abbreviations
ACPA: Anti-citrullinated protein antibody; ACR: American college of
rheumatology; AVERT: Assessing very early rheumatoid arthirits treatment;
AZA: Azathioprine; bDMARD: biological disease modifying antirheumatic
drug; BeSt: Behandel-Strategieën; CSA: Ciclosporin; DAS: Disease activity
score; EAC: Early arthritis clinic; EMPIRE: Etanercept and methotrexate in
patients to induce remission in early arthritis; ERAS: Early rheumatoid arthritis
study; HAQ: Health assessment questionnaire; HCQ: Hydroxychloroquine; HIT
HARD: High induction therapy with anti-rheumatic drugs; IL: Interleukin;
MRI: Magnetic resonance imaging; mTSS: modified total Sharp score;
MTX: Methotrexate; RA: Rheumatoid arthritis; RF: Rheumatoid factor;
RRR: Remission Induction by Remicade in RA; sDMARD: synthetic disease
modifying antirheumatic drug; SE: Shared epitope; SSA: Sulphasalazine;
TNF: Tumor necrosis factor.
Competing interests
RFvV has received research support from AbbVie, BMS, GSK, Pfizer, Roche
and UCB, and consultancy/honoraria from AbbVie, Biotest, BMS, GSK, Janssen,
Lilly, Merck, Pfizer, Roche, UCB and Vertex. GN has received consulting/speaking
fees from AbbVie, Berlin-Chemie Menarini, BMS, Egis, GSK, MSD, Pfizer, Roche,
Takeda and UCB.Authors’ contributions
GN and RFvV together wrote the manuscript. Both authors read and approved
the final manuscript.
Author details
1Department of Rheumatology, Semmelweis University, Faculty of Medicine,
Semmelweis University, Budapest 1023, Hungary. 2Department of Genetics,
Cell and Immunobiology, Faculty of Medicine, Semmelweis University,
Budapest 1089, Hungary. 3Unit for Clinical Therapy Research, Inflammatory
Diseases (ClinTRID), The Karolinska Institute, Stockholm 17176, Sweden.
References
1. Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, Burmester G,
et al. Treating rheumatoid arthritis to target: recommendations of an
international task force. Ann Rheum Dis. 2010;69:631–7.
2. Smolen JS, Landewé R, Breedveld FC, Buch M, Burmester G, Dougados M,
et al. EULAR recommendations for the management of rheumatoid arthritis
with synthetic and biological disease-modifying antirheumatic drugs: 2013
update. Ann Rheum Dis. 2014;73:492–509.
3. van Vollenhoven RF, Nagy G, Tak PP. Early start and stop of biologics: has
the time come? BMC Med. 2014;12:25.
4. van den Broek M, Huizinga TW, Dijkmans BA, Allaart CF. Drug-free remission:
is it already possible? Curr Opin Rheumatol. 2011;23:266–72.
5. Klareskog L, Catrina AI, Paget S. Rheumatoid arthritis. Lancet. 2009;373:659–72.
6. Baka Z, Buzás E, Nagy G. Rheumatoid arthritis and smoking: putting the
pieces together. Arthritis Res Ther. 2009;11:238.
7. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J
Med. 2011;365:2205–19.
8. McInnes IB, Schett G. Cytokines in the pathogenesis of rheumatoid arthritis.
Nat Rev Immunol. 2007;7:429–42.
9. Gabriel SE, Crowson CS, O’Fallon WM. Mortality in rheumatoid arthritis: have
we made an impact in 4 decades? J Rheumatol. 1999;26:2529–33.
10. McInnes IB, Liew FY. Cytokine networks - towards new therapies for
rheumatoid arthritis. Nat Clin Pract Rheumatol. 2005;1:31–9.
11. Genovese MC, Durez P, Richards HB, Supronik J, Dokoupilova E, Mazurov V,
et al. Efficacy and safety of secukinumab in patients with rheumatoid arthritis:
a phase II, dose-finding, double-blind, randomised, placebo controlled study.
Ann Rheum Dis. 2013;72:863–9.
12. Genovese MC, Durez P, Richards HB, Supronik J, Dokoupilova E, Aelion JA,
et al. One-year efficacy and safety results of secukinumab in patients with
rheumatoid arthritis: phase II, dose-finding, double-blind, randomized,
placebo-controlled study. J Rheumatol. 2014;41:414–21.
13. Schett G, Elewaut D, McInnes IB, Dayer JM, Neurath MF. How cytokine
networks fuel inflammation: toward a cytokine-based disease taxonomy. Nat
Med. 2013;19:822–4.
14. Quinn MA, Emery P. Window of opportunity in early rheumatoid arthritis:
possibility of altering the disease process with early intervention. Clin Exp
Rheumatol. 2003;21 Suppl 31:S154–7.
15. Boers M. Understanding the window of opportunity concept in early
rheumatoid arthritis. Arthritis Rheum. 2003;48:1771–4.
16. Raza K, Saber TP, Kvien TK, Tak PP, Gerlag DM. Timing the therapeutic
window of opportunity in early rheumatoid arthritis: proposal for definitions
of disease duration in clinical trials. Ann Rheum Dis. 2012;71:1921–3.
17. Aletaha D, Funovits J, Keystone EC, Smolen JS. Disease activity early in the
course of treatment predicts response to therapy after one year in
rheumatoid arthritis patients. Arthritis Rheum. 2007;56:3226–35.
18. Quinn MA, Conaghan PG, O’Connor PJ, Karim Z, Greenstein A, Brown A,
et al. Very early treatment with infliximab in addition to methotrexate in
early, poor-prognosis rheumatoid arthritis reduces magnetic resonance
imaging evidence of synovitis and damage, with sustained benefit after
infliximab withdrawal: results from a twelve-month randomized, double-blind,
placebo-controlled trial. Arthritis Rheum. 2005;52:27–35.
19. van der Bijl AE, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Ten Wolde S,
Han KH, van Krugten MV, et al. Infliximab and methotrexate as induction
therapy in patients with early rheumatoid arthritis. Arthritis Rheum.
2007;56:2129–34.
20. van den Broek M, Klarenbeek NB, Dirven L, van Schaardenburg D, Hulsmans HM,
Kerstens PJ, et al. Discontinuation of infliximab and potential predictors of
Nagy and van Vollenhoven Arthritis Research & Therapy  (2015) 17:181 Page 7 of 7persistent low disease activity in patients with early rheumatoid arthritis
and disease activity score-steered therapy: subanalysis of the BeSt study.
Ann Rheum Dis. 2011;70:1389–94.
21. Nam JL, Villeneuve E, Hensor EM, Conaghan PG, Keen HI, Buch MH, et al.
Remission induction comparing infliximab and high-dose intravenous steroid,
followed by treat-to-target: a double-blind, randomised, controlled trial in
new-onset, treatment-naive, rheumatoid arthritis (the IDEA study). Ann
Rheum Dis. 2014;73:75–85.
22. Tanaka Y, Takeuchi T, Mimori T, Saito K, Nawata M, Kameda H, et al.
Discontinuation of infliximab after attaining low disease activity in patients
with rheumatoid arthritis: RRR (remission induction by Remicade in RA)
study. Ann Rheum Dis. 2010;69:1286–91.
23. Smolen JS, Emery P, Fleischmann R, van Vollenhoven RF, Pavelka K, Durez P,
et al. Adjustment of therapy in rheumatoid arthritis on the basis of achievement
of stable low disease activity with adalimumab plus methotrexate or
methotrexate alone: the randomised controlled OPTIMA trial. Lancet.
2014;383:321–32.
24. Detert J, Bastian H, Listing J, Weiß A, Wassenberg S, Liebhaber A, et al.
Induction therapy with adalimumab plus methotrexate for 24 weeks followed
by methotrexate monotherapy up to week 48 versus methotrexate therapy
alone for DMARD-naive patients with early rheumatoid arthritis: HIT HARD, an
investigator-initiated study. Ann Rheum Dis. 2013;72:844–50.
25. Soubrier M, Puéchal X, Sibilia J, Mariette X, Meyer O, Combe B, et al. Evaluation
of two strategies (initial methotrexate monotherapy vs its combination with
adalimumab) in management of early active rheumatoid arthritis: data from
the GUEPARD trial. Rheumatology (Oxford). 2009;48:1429–34.
26. van der Kooij SM, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Güler-Yüksel
M, Zwinderman AH, Kerstens PJ, et al. Drug-free remission, functioning and
radiographic damage after 4 years of response-driven treatment in patients
with recent-onset rheumatoid arthritis. Ann Rheum Dis. 2009;68:914–21.
27. Klarenbeek NB, Güler-Yüksel M, van der Kooij SM, Han KH, Ronday HK,
Kerstens PJ, et al. The impact of four dynamic, goal-steered treatment
strategies on the 5-year outcomes of rheumatoid arthritis patients in the
BeSt study. Ann Rheum Dis. 2011;70:1039–46.
28. van der Woude D, Young A, Jayakumar K, Mertens BJ, Toes RE, van der
Heijde D, et al. Prevalence of and predictive factors for sustained disease-
modifying antirheumatic drug-free remission in rheumatoid arthritis: results
from two large early arthritis cohorts. Arthritis Rheum. 2009;60:2262–71.
29. van der Woude D, Visser K, Klarenbeek NB, Ronday HK, Peeters AJ, Kerstens PJ,
et al. Sustained drug-free remission in rheumatoid arthritis after DAS-driven or
non-DAS-driven therapy: a comparison of two cohort studies. Rheumatology
(Oxford). 2012;51:1120–8.
30. Nam JL, Villeneuve E, Hensor EM, Wakefield RJ, Conaghan PG, Green MJ,
et al. A randomised controlled trial of etanercept and methotrexate to
induce remission in early inflammatory arthritis: the EMPIRE trial. Ann
Rheum Dis. 2014;73:1027–36.
31. Emery P, Spieler W, Stopinska-Polaszewska M, Korshunov NI, Bukowski J,
Pedersen R, et al. Assessing maintenance of remission after withdrawal of
etanercept plus methotrexate, methotrexate alone, or placebo in early
rheumatoid arthritis patients who achieved remission with etanercept and
methotrexate: The Prize Study. Arthritis Rheum. 2013;65(10):2689.
32. Emery P, Burmester GR, Bykerk VP, Combe BG, Furst DE, Barré E, et al.
Evaluating drug-free remission with abatacept in early rheumatoid arthritis:
results from the phase 3b, multicentre, randomised, active-controlled AVERT
study of 24 months, with a 12-month, double-blind treatment period. Ann
Rheum Dis. 2014. doi:10.1136/annrheumdis-2014-206106.
33. Huizinga TW, Conaghan PG, Martin-Mola E, Schett G, Amital H, Xavier RM,
et al. Clinical and radiographic outcomes at 2 years and the effect of
tocilizumab discontinuation following sustained remission in the second
and third year of the ACT-RAY study. Ann Rheum Dis. 2014. doi:10.1136/
annrheumdis-2014-205752.
34. Nishimoto N, Amano K, Hirabayashi Y, Horiuchi T, Ishii T, Iwahashi M, et al.
Drug free REmission/low disease activity after cessation of tocilizumab
(Actemra) Monotherapy (DREAM) study. Mod Rheumatol. 2014;24:17–25.
35. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al.
The American Rheumatism Association 1987 revised criteria for the
classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315–24.
